MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571208 | Name: Chloroorienticin A

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Chloroorienticin A is a glycopeptide antibiotic.

Chemical Structure

Chloroorienticin A
Chloroorienticin A
CAS#118395-73-6

Theoretical Analysis

MedKoo Cat#: 571208

Name: Chloroorienticin A

CAS#: 118395-73-6

Chemical Formula: C73H88Cl2N10O26

Exact Mass: 1590.5248

Molecular Weight: 1592.45

Elemental Analysis: C, 55.06; H, 5.57; Cl, 4.45; N, 8.80; O, 26.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Chloroorienticin A; A82846B; A 82846B; A-82846B;
IUPAC/Chemical Name
N/A
InChi Key
XJHXLMVKYIVZTE-ZUDYGFIZSA-N
InChi Code
InChI=1S/C73H88Cl2N10O26/c1-26(2)14-38(79-7)64(96)84-54-56(91)30-9-12-42(36(74)16-30)106-44-18-32-19-45(60(44)111-71-61(58(93)57(92)46(25-86)108-71)110-49-24-73(6,78)63(95)28(4)105-49)107-43-13-10-31(17-37(43)75)59(109-48-23-72(5,77)62(94)27(3)104-48)55-69(101)83-53(70(102)103)35-20-33(87)21-41(89)50(35)34-15-29(8-11-40(34)88)51(66(98)85-55)82-67(99)52(32)81-65(97)39(22-47(76)90)80-68(54)100/h8-13,15-21,26-28,38-39,46,48-49,51-59,61-63,71,79,86-89,91-95H,14,22-25,77-78H2,1-7H3,(H2,76,90)(H,80,100)(H,81,97)(H,82,99)(H,83,101)(H,84,96)(H,85,98)(H,102,103)/t27-,28-,38+,39-,46+,48-,49-,51+,52+,53-,54+,55-,56+,57+,58+,59+,61+,62-,63-,71-,72-,73-/m0/s1
SMILES Code
O=C([C@H](NC([C@@H](CC(C)C)NC)=O)[C@@H](C1=CC(Cl)=C(OC2=CC3=CC(OC4=C(Cl)C=C([C@H]([C@@H]5N6)O[C@@H]7O[C@@H](C)[C@H](O)[C@](N)(C)C7)C=C4)=C2O[C@H]8[C@H](O[C@@H]9O[C@@H](C)[C@H](O)[C@@](C)(N)C9)[C@H](O)[C@H](O)[C@@H](CO)O8)C=C1)O)N[C@@H](CC(N)=O)C(N[C@H]3C(N[C@H](C%10=CC(C%11=C(O)C=C(C=C%11[C@H](NC5=O)C(O)=O)O)=C(O)C=C%10)C6=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,592.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Allen NE, LeTourneau DL, Hobbs JN Jr, Thompson RC. Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies. Antimicrob Agents Chemother. 2002 Aug;46(8):2344-8. PubMed PMID: 12121903; PubMed Central PMCID: PMC127376. 2: Pavlov AIu, Preobrazhenskaia MN. [Chemical modification of glycopeptide antibiotics]. Bioorg Khim. 1998 Sep;24(9):644-62. Review. Russian. PubMed PMID: 9813730. 3: Rodriguez MJ, Snyder NJ, Zweifel MJ, Wilkie SC, Stack DR, Cooper RD, Nicas TI, Mullen DL, Butler TF, Thompson RC. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci. J Antibiot (Tokyo). 1998 Jun;51(6):560-9. PubMed PMID: 9711219. 4: LeTourneau DL, Allen NE. Use of capillary electrophoresis to measure dimerization of glycopeptide antibiotics. Anal Biochem. 1997 Mar 1;246(1):62-6. PubMed PMID: 9056183. 5: Allen NE, LeTourneau DL, Hobbs JN Jr. Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Antimicrob Agents Chemother. 1997 Jan;41(1):66-71. PubMed PMID: 8980756; PubMed Central PMCID: PMC163661. 6: Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. PubMed PMID: 8878606; PubMed Central PMCID: PMC163498. 7: Cooper RD, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo). 1996 Jun;49(6):575-81. PubMed PMID: 8698642. 8: Linsdell H, Toiron C, Bruix M, Rivas G, Menéndez M. Dimerization of A82846B, vancomycin and ristocetin: influence on antibiotic complexation with cell wall model peptides. J Antibiot (Tokyo). 1996 Feb;49(2):181-93. PubMed PMID: 8621360. 9: Prowse WG, Kline AD, Skelton MA, Loncharich RJ. Conformation of A82846B, a glycopeptide antibiotic, complexed with its cell wall fragment: an asymmetric homodimer determined using NMR spectroscopy. Biochemistry. 1995 Jul 25;34(29):9632-44. PubMed PMID: 7626632. 10: Ena J, Houston A, Wenzel RP, Jones RN. Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital. J Chemother. 1993 Feb;5(1):17-21. PubMed PMID: 8459260. 11: Perl TM, Wenzel RP, Jones RN. In-vitro activity of LY264826, an investigational glycopeptide antibiotic, against gram-positive bloodstream isolates and selected gram-negative bacilli. J Antimicrob Chemother. 1992 May;29(5):596-8. PubMed PMID: 1624399. 12: Nishino T. [Recent trend and development of novel antimicrobial agents for MRSA infections]. Nihon Rinsho. 1992 May;50(5):1066-74. Review. Japanese. PubMed PMID: 1324332. 13: Watanakunakorn C. In vitro activity of the new glycopeptide LY264826 versus vancomycin against clinical isolates of enterococci. Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):982-3. PubMed PMID: 1794373. 14: Nagarajan R, Berry DM, Schabel AA. The structural relationships of A82846B and its hydrolysis products with chloroorienticins A, B and C. J Antibiot (Tokyo). 1989 Sep;42(9):1438-40. PubMed PMID: 2793597. 15: Watanakunakorn C. Comparison of LY264826-gentamicin with vancomycin-gentamicin against enterococci from blood cultures. J Antimicrob Chemother. 1992 Mar;29(3):303-6. PubMed PMID: 1592699. 16: Chin NX, Neu HC. In vitro activity of LY264826 compared to other glycopeptides and daptomycin. Diagn Microbiol Infect Dis. 1991 Mar-Apr;14(2):181-4. PubMed PMID: 1651826. 17: Rolston KV, Nguyen H, Messer M. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer. Antimicrob Agents Chemother. 1990 Nov;34(11):2137-41. PubMed PMID: 2149921; PubMed Central PMCID: PMC172013. 18: Fasola EL, Moody JA, Gerding DN, Peterson LR. In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile. Antimicrob Agents Chemother. 1990 Oct;34(10):2007-8. PubMed PMID: 2291667; PubMed Central PMCID: PMC171979. 19: Tsuji N, Kamigauchi T, Kobayashi M, Terui Y. New glycopeptide antibiotics: II. The isolation and structures of chloroorienticins. J Antibiot (Tokyo). 1988 Oct;41(10):1506-10. PubMed PMID: 3272137.